Cancer Stem Cell News Volume 10.41 | Oct 20 2021


    2021-10-20 | CSCN 10.41

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.41 – 20 October, 2021

    Signatures of Plasticity, Metastasis, and Immunosuppression in an Atlas of Human Small Cell Lung Cancer

    Scientists sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 small cell lung cancer (SCLC) transcriptomes. They observed greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes.
    [Cancer Cell]

    AbstractGraphical Abstract
    How have LSCs changed our understanding of myeloid malignancies? Webinar by Dr. Christopher Park, NYU
    PUBLICATIONSRanked by the impact factor of the journal

    Circular RNA circIPO11 Drives Self-Renewal of Liver Cancer Initiating Cells via Hedgehog Signaling

    CircIPO11 was highly expressed in hepatocellular carcinoma (HCC) tumor tissues and liver CSCs, and was required for the self-renewal maintenance of liver CSCs to initiate HCC development.
    [Molecular Cancer]

    Full Article

    Interleukin-30 Feeds Breast Cancer Stem Cells via CXCL10 and IL23 Autocrine Loops and Shapes Immune Contexture and Host Outcome

    Human and murine breast CSCs were tested for their production of and response to interleukin-30 by using flow cytometry, confocal microscopy, proliferation and sphere-formation assays, and PCR array.
    [Journal For Immunotherapy of Cancer]


    Tumor Microenvironment-Based Screening Repurposes Drugs Targeting Cancer Stem Cells and Cancer-Associated Fibroblasts

    Lung cancer patient-derived cancer cell and cancer-associated fibroblasts were utilized to mimic the tumor microenvironment and reproduced the stemness properties of CSCs in vitro and developed a high-throughput drug screening platform with phenotypical parameters.

    Full ArticleGraphical Abstract

    L1CAM Promotes Ovarian Cancer Stemness and Tumor Initiation via FGFR1/SRC/STAT3 Signaling

    The genetic manipulation of L1CAM in ovarian carcinoma (OC) cells provided gain and loss-of-function models that were then employed in cell biological assays as well as in vivo tumorigenesis experiments to assess the role of L1CAM in OC cell stemness and in ovarian OSC-driven tumor initiation.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    Musarin, a Novel Protein with Tyrosine Kinase Inhibitory Activity from Trametes versicolor, Accepted Inhibits Colorectal Cancer Stem Cell Growth

    Researchers characterized a novel 12-kDa protein that named musarin, which was purified from Trametes versicolor mushroom extract and showed significant growth inhibition on multiple human colorectal cancer cell lines in vitro.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract

    Antioxidant and Antiproliferative Potential of Ethanolic Extracts from Moringa oleifera, Tropaeolum tuberosum and Annona cherimola in Colorectal Cancer Cells

    The extract of A. cherimola showed the highest antioxidant activity and M. oleifera had the highest capacity to enhance the activity of detoxifying enzymes such as glutathione S-transferase and quinone oxidoreductase.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract

    EGFR Is a Pivotal Player of the E2/ERβ – Mediated Functional Properties, Aggressiveness and Stemness in Triple-Negative Breast Cancer Cells

    The authors reported on the epidermal growth factor receptor (EGFR)-estrogen receptor beta (ERβ) functional relationship in connection to the aggressiveness and CSC-like characteristics of triple-negative breast cancer cells.
    [FEBS Journal]

    Full Article

    miR-3065-3p Promotes Stemness and Metastasis by Targeting CRLF1 in Colorectal Cancer

    The expression of miR-3065-3p in colorectal cancer and the association of miR-3065-3p expression with prognosis of patients with colorectal cancer were analyzed using TCGA dataset or clinical cases.
    [Journal of Translational Medicine]

    Full Article

    Gastric Cancer Stem Cells Survive in Stress Environments via Their Autophagy System

    Scientists clarified the significance of autophagy systems of CSCs under stress environments. Four gastric cancer cell line were used.
    [Scientific Reports]

    Full Article

    Synergistic Killing Effects of PD-L1-CAR T Cells and Colorectal Cancer Stem Cell-Dendritic Cell Vaccine-Sensitized T Cells in ALDH1-Positive Colorectal Cancer Stem Cells

    Investigators evaluated programmed cell death ligand-1 (PD-L1) expression in colorectal CSCs (CCSCs) and non-CCSCs and designed a combination immunotherapy synchronously utilizing PD-L1-chimeric antigen receptor T (CAR)-T cells together with CCSC-dendritic cells vaccine-sensitized T cells for the treatment of colorectal cancer.
    [Journal of Cancer]

    Full ArticleGraphical Abstract
    He needed a better model system. So he invented a new organoid. Watch James Wells' webinar.

    LINC00662: A New Oncogenic lncRNA with Great Potential

    LINC00662 can reduce the promoter methylation level of s-adenosylmethionine-dependent hepatocellular carcinoma-promoting genes by regulating the MAT1A/SAM and AHCY/SAH axes, thereby promoting the activation of oncogenes.
    [Journal of Cellular Physiology]


    Taking The Road Less Traveled – The Therapeutic Potential of CBP/β-Catenin Antagonists

    Scientists discuss the challenges of targeting the Wnt signaling cascade, the safety, efficacy, and therapeutic potential of specific CBP/β-catenin antagonists and a rationale for the pleiotropic effects of CBP/β-catenin antagonists beyond Wnt signaling.
    [Expert Opinion On Therapeutic Targets]


    Geron Announces Completion of Patient Enrollment in IMerge Phase III Clinical Trial in Lower Risk Myelodysplastic Syndromes

    Geron Corporation announced the completion of patient enrollment in the IMerge Phase III clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes.
    [NGeron Corporation]

    Press Release

    Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (Lenvatinib) in Two Different Types of Cancer

    Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted positive opinions recommending approval of the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA.
    [Merck (BusinessWire, Inc.)]

    Press Release

    American College of Toxicology Annual Meeting

    November 10 – 19, 2021

    > See All Events


    Postdoctoral Scientist – Translational Cancer Biology and Therapeutics

    Cedars-Sinai Medical Center – Los Angeles, California, United States

    Research Assistant – Hematology/Leukemia Research

    University of Cambridge – Cambridge, England, United Kingdom

    Postdoctoral position – Pancreatic Adenocarcinoma

    University of California Los Angeles – Los Angeles, California, United States

    Postdoctoral Scientist – Skin Cancer and Aging Group

    Cancer Research UK Manchester Institute – Manchester, United Kingdom

    Assistant Professor – Cancer Research

    University of Manitoba – Winnipeg, Manitoba, Canada

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter